RESTYLANE NASHA
FDA premarket approval P040024/S113 · decided 2019-06-20
Approval details
- PMA number
- P040024
- Supplement
- S113
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- RESTYLANE NASHA
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Q-Med AB
- Date received
- 2019-05-21
- Decision date
- 2019-06-20
- Days to decision
- 30 days
- Decision code
- OK30
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Uppsala
- Statement
- Outsourcing the method of analysis for D-value determination of biological indicators produced by Galderma Uppsala, Sweden.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.